Sponsor hub

Baylor College of Medicine clinical trial failures

Review 72 stopped clinical trials from Baylor College of Medicine, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 1 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials72
Likely biological signals1
Shown below72

Dominant stop reasons

OPERATIONAL
41
OTHER/UNKNOWN
30
SAFETY
1

Notable sponsors

Baylor College of Medicine
72

Related phases

Phase I
20
Phase II
19
Phase IV
13
Unknown
13
Early Phase I
4

Crawlable stopped-trial records

Open Explore

Showing up to 72 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT05405257: Oxytocin for Hypermobile Ehlers-Danlos Syndrome

Phase I Hypermobile Ehlers-Danlos Syndrome trial by Baylor College of Medicine. Stop reason: OPERATIONAL.

Study team has decided to close the trial (NCT05405257) due problems with patient recruitment and enrollment efforts. To date, only one patient completed both arms.

NCT01774487: Pentoxifylline Therapy in Biliary Atresia

Phase II Biliary Atresia trial by Baylor College of Medicine. Stop reason: OPERATIONAL.

Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.

NCT04401410: Anti-SARS Cov-2 T Cell Infusions for COVID 19

Phase I SARS-CoV 2 trial by Baylor College of Medicine. Stop reason: OPERATIONAL.

Due to trial's eligibility criteria and the low census of hospitalized COVID-19 patients meeting eligibility criteria, the Sponsor will be unable to enroll a meaningful number of patients in this single-center trial in a reasonable time frame.